Conmind Medical (聚芯医疗)

Conmind Medical operates at the intersection of neurovascular and structural-heart devices rather than concentrating on a single procedure category. Its disclosed portfolio includes the HaloChord system for transapical mitral chordal repair and HaloStitch for catheter-based PFO closure, while its broader technology set includes J-Tube, Crassula, and Kapflex neurointerventional systems. This gives the company a wider procedural footprint than a narrowly focused device developer, but also creates a more demanding regulatory, clinical, and commercialization agenda. The company describes an integrated model combining medical, engineering, academic, clinical, manufacturing, and commercialization capabilities. Website materials cite more than 200 employees, over 200 patent applications, access to more than 200 hospitals, and activity in more than 20 countries and regions. Relative to the information available, Conmind’s differentiators are its combined neurovascular and structural-heart scope, in-house device development, and emphasis on minimally invasive intervention. Its market position should therefore be assessed as an expanding China-based platform with international ambitions, rather than as an established global category leader.

Conmind Medical shows a financing-led expansion trajectory since its 2020 founding. The company raised approximately $13.87 million in its Series B on Aug 21, 2023 and approximately $29.08 million in Series C financing on Apr 7, 2026. The later round was more than twice the size of the Series B in dollar terms, indicating increased institutional backing and a larger capital base for clinical development, manufacturing, and commercialization. The company reports an employee range of 101-250 in structured records, while its website describes a workforce of more than 200, suggesting that the organization has reached meaningful scale for an early-stage medical-device manufacturer. Its product expansion also points to multiple growth vectors: HaloChord and HaloStitch address structural-heart procedures, while J-Tube, Crassula, and Kapflex support neurovascular applications. The stated reach of more than 200 hospitals and over 20 countries and regions indicates distribution and commercialization progress, although revenue, regulatory timelines by product, and hiring velocity are not publicly detailed. The principal trajectory risk is execution complexity across several clinical specialties and geographies.